ATA1302001A - Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen - Google Patents

Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen

Info

Publication number
ATA1302001A
ATA1302001A AT0013001A AT1302001A ATA1302001A AT A1302001 A ATA1302001 A AT A1302001A AT 0013001 A AT0013001 A AT 0013001A AT 1302001 A AT1302001 A AT 1302001A AT A1302001 A ATA1302001 A AT A1302001A
Authority
AT
Austria
Prior art keywords
specific pathogen
isolating
identifying
antigens against
producing antigens
Prior art date
Application number
AT0013001A
Other languages
English (en)
Other versions
AT410798B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to AT0013001A priority Critical patent/AT410798B/de
Priority to CNA028057651A priority patent/CN1649894A/zh
Priority to CA2436057A priority patent/CA2436057C/en
Priority to EP05024214.8A priority patent/EP1630172B1/de
Priority to EP10178465A priority patent/EP2322539A3/de
Priority to NZ565349A priority patent/NZ565349A/en
Priority to CNA2008101610502A priority patent/CN101492496A/zh
Priority to EP05108422A priority patent/EP1616876A3/de
Priority to HU0402048A priority patent/HUP0402048A3/hu
Priority to PCT/EP2002/000546 priority patent/WO2002059148A2/en
Priority to EP02716669A priority patent/EP1355930B1/de
Priority to EP10178476A priority patent/EP2319861A1/de
Priority to AT02716669T priority patent/ATE309268T1/de
Priority to KR1020087006114A priority patent/KR100901915B1/ko
Priority to CA2792244A priority patent/CA2792244A1/en
Priority to PL392964A priority patent/PL214482B1/pl
Priority to EP10178468A priority patent/EP2412722A1/de
Priority to US10/470,048 priority patent/US7968297B2/en
Priority to NZ551802A priority patent/NZ551802A/xx
Priority to MXPA03006702A priority patent/MXPA03006702A/es
Priority to KR1020097017433A priority patent/KR20090101973A/ko
Priority to DK02716669T priority patent/DK1355930T3/da
Priority to DE60207194T priority patent/DE60207194T2/de
Priority to BR0207067-7A priority patent/BR0207067A/pt
Priority to PL367125A priority patent/PL209115B1/pl
Priority to NZ527440A priority patent/NZ527440A/xx
Priority to SK1049-2003A priority patent/SK10492003A3/sk
Priority to CZ20032201A priority patent/CZ20032201A3/cs
Priority to IL15708202A priority patent/IL157082A0/xx
Priority to RU2003125967/13A priority patent/RU2289817C2/ru
Priority to KR1020087026439A priority patent/KR20080107477A/ko
Priority to AU2002247641A priority patent/AU2002247641B8/en
Priority to NZ540764A priority patent/NZ540764A/en
Priority to JP2002559450A priority patent/JP2004531476A/ja
Priority to KR1020037009882A priority patent/KR100851728B1/ko
Priority to ES02716669T priority patent/ES2252438T3/es
Publication of ATA1302001A publication Critical patent/ATA1302001A/de
Application granted granted Critical
Priority to IS6895A priority patent/IS6895A/is
Priority to NO20033364A priority patent/NO20033364L/no
Priority to ZA200305764A priority patent/ZA200305764B/en
Publication of AT410798B publication Critical patent/AT410798B/de
Priority to AU2006249236A priority patent/AU2006249236B2/en
Priority to US11/614,716 priority patent/US7771728B2/en
Priority to IL186706A priority patent/IL186706A/en
Priority to AU2007234519A priority patent/AU2007234519B2/en
Priority to JP2008152742A priority patent/JP5053933B2/ja
Priority to AU2010200549A priority patent/AU2010200549A1/en
Priority to US12/853,074 priority patent/US8323660B2/en
Priority to IL211037A priority patent/IL211037A/en
Priority to IL211038A priority patent/IL211038A0/en
Priority to US13/613,761 priority patent/US8715688B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT0013001A 2001-01-21 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen AT410798B (de)

Priority Applications (49)

Application Number Priority Date Filing Date Title
AT0013001A AT410798B (de) 2001-01-26 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CNA028057651A CN1649894A (zh) 2001-01-26 2002-01-21 鉴定,分离及生产特异性病原体抗原的方法
CA2436057A CA2436057C (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
EP05024214.8A EP1630172B1 (de) 2001-01-26 2002-01-21 Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
EP10178465A EP2322539A3 (de) 2001-01-26 2002-01-21 Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
NZ565349A NZ565349A (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
CNA2008101610502A CN101492496A (zh) 2001-01-26 2002-01-21 鉴定,分离及生产特异性病原体抗原的方法
EP05108422A EP1616876A3 (de) 2001-01-26 2002-01-21 Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
HU0402048A HUP0402048A3 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
PCT/EP2002/000546 WO2002059148A2 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
EP02716669A EP1355930B1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
EP10178476A EP2319861A1 (de) 2001-01-26 2002-01-21 Verfahren zur Identifikation, Isolierung und Herstellung von Antigenen gegen spezifische Pathogene
AT02716669T ATE309268T1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
KR1020087006114A KR100901915B1 (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는방법
CA2792244A CA2792244A1 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
PL392964A PL214482B1 (pl) 2001-01-26 2002-01-21 Antygen reaktywny wobec surowicy hiperimmunologicznej, zastosowanie tego antygenu, preparat farmaceutyczny zawierajacy antygen, szczepionka, przeciwcialo, preparat zawierajacy przeciwcialo, sposób wytwarzania preparatu i czasteczka kwasu nukleinowego
EP10178468A EP2412722A1 (de) 2001-01-26 2002-01-21 Verfahren zur Identifikation, Isolierung und Herstellung von Antigenen gegen spezifische Pathogene
US10/470,048 US7968297B2 (en) 2001-01-26 2002-01-21 Method for identification, isolation and production of antigens to a specific pathogen
NZ551802A NZ551802A (en) 2001-01-26 2002-01-21 A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof
MXPA03006702A MXPA03006702A (es) 2001-01-26 2002-01-21 Metodo para la identificacion, aislamiento y produccion de antigenos para un patogeno especifico.
KR1020097017433A KR20090101973A (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는 방법
DK02716669T DK1355930T3 (da) 2001-01-26 2002-01-21 Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
DE60207194T DE60207194T2 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
BR0207067-7A BR0207067A (pt) 2001-01-26 2002-01-21 Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
PL367125A PL209115B1 (pl) 2001-01-26 2002-01-21 Sposób identyfikowania, izolowania i wytwarzania antygenów od specyficznego patogenu
NZ527440A NZ527440A (en) 2001-01-26 2002-01-21 A method for indentification, isolation and production of antigens to a specific pathogen
SK1049-2003A SK10492003A3 (sk) 2001-01-26 2002-01-21 Spôsob identifikácie, izolácie a produkcie antigénov špecifického patogénu
CZ20032201A CZ20032201A3 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
IL15708202A IL157082A0 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
RU2003125967/13A RU2289817C2 (ru) 2001-01-26 2002-01-21 Способ идентификации, выделения и получения антигенов определенного патогена
KR1020087026439A KR20080107477A (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는 방법
AU2002247641A AU2002247641B8 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
NZ540764A NZ540764A (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
JP2002559450A JP2004531476A (ja) 2001-01-26 2002-01-21 特定の病原体に対する抗原の同定、単離および製造方法
KR1020037009882A KR100851728B1 (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는 방법
ES02716669T ES2252438T3 (es) 2001-01-26 2002-01-21 Procedimiento para la identificacion, aislamiento y produccion de antigenos para un patogeno especifico.
IS6895A IS6895A (is) 2001-01-26 2003-07-25 Aðferð til að bera kennsl á, einangra og vinna mótefnavaka við ákveðnum sjúkdómsvaldi
NO20033364A NO20033364L (no) 2001-01-26 2003-07-25 Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen
ZA200305764A ZA200305764B (en) 2001-01-26 2003-07-25 A method for identification, isolation and production of antigens to a specific pathogen.
AU2006249236A AU2006249236B2 (en) 2001-01-26 2006-12-04 A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen
US11/614,716 US7771728B2 (en) 2001-01-21 2006-12-21 Method for identification, isolation and production of antigens to a specific pathogen
IL186706A IL186706A (en) 2001-01-26 2007-10-17 Method for identification, isolation and production of antigens to a specific pathogen
AU2007234519A AU2007234519B2 (en) 2001-01-26 2007-11-16 A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen
JP2008152742A JP5053933B2 (ja) 2001-01-26 2008-06-11 特定の病原体に対する抗原の同定、単離および製造方法
AU2010200549A AU2010200549A1 (en) 2001-01-26 2010-02-12 A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen
US12/853,074 US8323660B2 (en) 2001-01-26 2010-08-09 Method for identification, isolation and production of antigens to a specific pathogen
IL211037A IL211037A (en) 2001-01-26 2011-02-03 Antigen @ reactant @ with @ serum @ hyper
IL211038A IL211038A0 (en) 2001-01-26 2011-02-03 A method for identification, isolation and production of antigens to a specific pathogen
US13/613,761 US8715688B2 (en) 2001-01-26 2012-09-13 Method for identification, isolation and production of antigens to a specific pathogen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0013001A AT410798B (de) 2001-01-26 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen

Publications (2)

Publication Number Publication Date
ATA1302001A true ATA1302001A (de) 2002-12-15
AT410798B AT410798B (de) 2003-07-25

Family

ID=3636418

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0013001A AT410798B (de) 2001-01-21 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AT02716669T ATE309268T1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02716669T ATE309268T1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens

Country Status (24)

Country Link
US (4) US7968297B2 (de)
EP (6) EP1355930B1 (de)
JP (2) JP2004531476A (de)
KR (4) KR20080107477A (de)
CN (2) CN1649894A (de)
AT (2) AT410798B (de)
AU (3) AU2002247641B8 (de)
BR (1) BR0207067A (de)
CA (2) CA2792244A1 (de)
CZ (1) CZ20032201A3 (de)
DE (1) DE60207194T2 (de)
DK (1) DK1355930T3 (de)
ES (1) ES2252438T3 (de)
HU (1) HUP0402048A3 (de)
IL (4) IL157082A0 (de)
IS (1) IS6895A (de)
MX (1) MXPA03006702A (de)
NO (1) NO20033364L (de)
NZ (4) NZ527440A (de)
PL (2) PL214482B1 (de)
RU (1) RU2289817C2 (de)
SK (1) SK10492003A3 (de)
WO (1) WO2002059148A2 (de)
ZA (1) ZA200305764B (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1353689T3 (da) 2001-01-03 2006-07-31 Epitopix Llc Immuniseringspræparater og anvendelse deraf
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2320233A1 (de) 2001-06-15 2011-05-11 Inhibitex, Inc. Kreuzreaktive monoklonale und polyklonale Antikörper, die Oberflächenprotein aus Koagulasenegativen Staphylococci und Staphylococcus aureus erkennen
GB0200865D0 (en) * 2002-01-16 2002-03-06 Univ Bristol Method
GB2387600A (en) * 2002-04-19 2003-10-22 Pantherix Ltd Pantothenate kinase
WO2004030699A1 (en) * 2002-10-03 2004-04-15 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
EP1601770B1 (de) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigene
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
CN1774447B (zh) 2003-04-15 2011-04-06 英特塞尔股份公司 肺炎链球菌抗原
WO2004094467A2 (en) * 2003-04-22 2004-11-04 Intercell Ag H. pylori antigens
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
EP2327720A1 (de) 2003-05-30 2011-06-01 Intercell AG Enterokokken-Antigene
RU2257217C2 (ru) * 2003-07-08 2005-07-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Гипериммунный тканевой препарат
US20060188515A1 (en) * 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
SI1651166T1 (sl) * 2003-07-24 2010-06-30 Merck Sharp & Dohme Polipeptidi za induciranje zaščitnega imunskegaodgovora proti stafilokoknem eureusu
WO2005028665A2 (en) 2003-09-19 2005-03-31 Epitopix, Llc Campylobacter polypeptides and methods of use
EP1725575B1 (de) * 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptide zur induktion einer protektiven immunantwort gegen staphylococcus aureus
US20070172498A1 (en) * 2004-02-27 2007-07-26 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
JP2005278537A (ja) * 2004-03-30 2005-10-13 Dai Ichi Seiyaku Co Ltd 新規ポリペプチド
JP2008508855A (ja) * 2004-04-27 2008-03-27 インターツェル・アクチェンゲゼルシャフト Ｔｄ抗原
US7842479B2 (en) 2004-05-21 2010-11-30 The Board Of Regents Of The University Of Nebraska Methods for altering acetic acid production and enhancing cell death in bacteria
CA2565330A1 (en) * 2004-05-25 2005-12-08 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1781326A4 (de) * 2004-06-04 2009-01-14 Pharmexa Inc Induktion einer immunantwort gegen streptokokkenpneumonie-polysacchariden
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
WO2007018482A2 (en) * 2004-07-06 2007-02-15 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2007001361A2 (en) * 2004-09-17 2007-01-04 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP2181714A3 (de) 2004-09-22 2010-06-23 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
EP2340848A3 (de) 2004-10-21 2011-09-14 Wyeth LLC Immunogene Zusammensetzungen von Staphylococcus epidermidis Polypeptide und Polynucleotide Antigenen
AU2005298742B2 (en) * 2004-10-29 2010-08-12 Intercell Ag HCV vaccines for chronic HCV patients
CN101432017B (zh) 2005-01-21 2011-12-21 默沙东公司 用于诱导针对金黄色葡萄球菌的保护性免疫应答的多肽
EP2431382A1 (de) 2005-01-21 2012-03-21 Epitopix, LLC Yersinia ssp., Polypeptide und Verwendungsverfahren
NZ613923A (en) 2005-02-14 2015-02-27 Epitopix Llc Antibody compositions that bind polypeptides from staphylococcus aureus
JP2008534970A (ja) * 2005-04-04 2008-08-28 ヴィヴェンティア バイオテック インコーポレーティッド 抗原の同定のための方法および系
WO2006121664A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
WO2007007352A2 (en) * 2005-07-14 2007-01-18 Bharat Biotech International Limited A vaccine for staphylococcal infections
CA2637598A1 (en) * 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
SG170090A1 (en) 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
CN101516905A (zh) * 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
US20080102067A1 (en) * 2006-10-25 2008-05-01 Cook Mark E Immunogenic composition
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP1935984A1 (de) * 2006-12-20 2008-06-25 Unilever N.V. Screening-Verfahren zur Identifizierung eines Konservierungsmittels
WO2008140632A2 (en) 2007-01-24 2008-11-20 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus epidermidis
WO2008115415A2 (en) * 2007-03-19 2008-09-25 Merck & Co., Inc Polypeptides for inducing a protective immune response against staphylococcus epidermidis
CN101883782A (zh) * 2007-06-18 2010-11-10 英特塞尔股份公司 衣原体抗原
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR101661946B1 (ko) 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
CN101827932B (zh) * 2007-10-18 2013-03-13 荷兰联合利华有限公司 制备发泡剂的方法
CN101458255B (zh) * 2007-12-14 2013-03-06 武汉大学 丙型肝炎病毒包膜抗原夹心法试剂盒及检测方法
US20090196852A1 (en) * 2008-02-04 2009-08-06 Watkinson D Tobin Compositions and methods for diagnosing and treating immune disorders
CA2716706C (en) 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
JP2011514167A (ja) 2008-03-17 2011-05-06 インターセル アーゲー 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
WO2009158682A2 (en) * 2008-06-27 2009-12-30 Watkinson D Tobin Compositions and methods for diagnosing and treating pathogenic disorders
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US8318180B2 (en) * 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
CA2739581A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2010043520A1 (en) * 2008-10-16 2010-04-22 Unilever Plc Hydrophobin solution containing antifoam
WO2010062814A1 (en) 2008-11-26 2010-06-03 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
US20110229508A1 (en) 2008-11-26 2011-09-22 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
RU2371201C1 (ru) * 2008-12-15 2009-10-27 Гурий Петрович Ступаков Способ лечения хронических заболеваний
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
EP2424882A2 (de) 2009-02-05 2012-03-07 Intercell AG Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
BRPI1011856A2 (pt) 2009-03-23 2020-11-03 Epitopix, Llc polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
SG174968A1 (en) * 2009-04-03 2011-11-28 Univ Chicago Compositions and methods related to protein a (spa) variants
CA2758490C (en) * 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
CA2704702C (en) * 2009-06-02 2018-06-12 Unilever Plc Aerated baked products
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
SG176837A1 (en) 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
CN103025352B (zh) * 2010-05-05 2017-07-11 纽约大学 金黄色葡萄球菌杀白细胞素及其治疗组合物和用途
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2593133A4 (de) 2010-07-13 2014-11-26 Merck Sharp & Dohme Staphylococcus aureus-oberflächenprotein sa1789 und darauf basierender schutzimpfstoff
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
EP2638058B1 (de) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase-peptid-konjugat-impfstoffe gegen staphylococcus aureus
CN102558316B (zh) * 2010-12-30 2015-07-01 上海雅心生物技术有限公司 高稳定性的具抗体结合能力的重组蛋白a及其生产
US8945588B2 (en) * 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2720754B1 (de) 2011-06-19 2016-10-19 New York University Leukotoxin e/d als neue entzündungshemmer und mikrobizide
NZ764564A (en) * 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
RU2526497C2 (ru) * 2012-10-31 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохарнения и социального развития Российской Федерации Способ определения генотипов золотистого стафилококка
HUE049012T2 (hu) * 2012-11-06 2020-09-28 Medimmune Llc Antitestek S. aureus felszíni determinánsok ellen
WO2014096333A1 (en) * 2012-12-20 2014-06-26 Morphosys Ag Anti-staphylococcal antibodies
CN103965336B (zh) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
AU2014258109B2 (en) * 2013-04-25 2016-09-29 Abtlas Co., Ltd. Method for refining protein including self-cutting cassette and use thereof
JP6767865B2 (ja) * 2013-08-28 2020-10-14 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合する安定なポリペプチド
MY176200A (en) 2013-08-28 2020-07-24 Affibody Ab Binding polypeptides having a mutated scaffold
CN104558196A (zh) * 2013-10-15 2015-04-29 温州医科大学 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途
RU2542396C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ и набор для ускоренной лабораторной диагностики коклюшной инфекции
EP4227685A3 (de) * 2013-12-03 2024-02-28 Evaxion Biotech A/S Proteine und nukleinsäuren für impfstoffe gegen staphylococcus aureus
CN103694323B (zh) * 2013-12-09 2017-01-18 成都欧林生物科技股份有限公司 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
CN113694191A (zh) * 2014-06-30 2021-11-26 默多克儿童研究所 螺杆菌治疗剂
CN104569386B (zh) * 2014-12-10 2016-05-11 中国水产科学研究院淡水渔业研究中心 一种罗非鱼源无乳链球菌elisa快速检测试剂盒及其检测方法
MX376535B (es) * 2014-12-17 2025-03-07 Hoffmann La Roche Reacción enzimática en un solo recipiente para conjugación de polipéptido doble en un solo paso usando sortasa.
US10781246B2 (en) 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
EP3353310B1 (de) 2015-09-25 2020-04-29 H. Hoffnabb-La Roche Ag Verfahren zur herstellung von thioestern unter verwendung einer sortase a
CN108026560A (zh) 2015-09-25 2018-05-11 豪夫迈·罗氏有限公司 在低共熔溶剂中使用分选酶的转酰胺反应
JP6998862B2 (ja) 2015-09-25 2022-02-04 エフ．ホフマン－ラ ロシュ アーゲー 可溶性ソルターゼａ
SG11201804402WA (en) 2015-11-27 2018-06-28 Univ Masarykova Thermostable fgf2 polypeptide, use thereof
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10504742B2 (en) * 2017-05-31 2019-12-10 Asm Ip Holding B.V. Method of atomic layer etching using hydrogen plasma
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
EP4410802A3 (de) 2018-02-12 2024-10-30 Inimmune Corporation Toll-like-rezeptorliganden
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
RU2689161C1 (ru) * 2018-10-04 2019-05-24 Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения бактериальных антигенов
KR20220025724A (ko) 2019-05-14 2022-03-03 더 유니버서티 오브 시카고 스타필로코커스 단백질 Ａ(ＳｐＡ) 변이체를 포함하는 방법 및 조성물
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
CN111110838A (zh) * 2019-12-24 2020-05-08 华南师范大学 一种罗非鱼无乳链球菌疫苗及其制备方法
EP4154003A1 (de) * 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Verfahren zur bestimmung der wirksamkeit von antigenen
CN111808977B (zh) * 2020-07-23 2023-06-27 清华大学深圳国际研究生院 一种由snp所引起利福平类抗生素耐药的抗性基因的特异性引物的设计方法及检测方法
US11820989B2 (en) 2020-11-04 2023-11-21 Eligo Bioscience Phage-derived particles for in situ delivery of DNA payload into C. acnes population
KR102281369B1 (ko) * 2021-04-07 2021-07-22 씨제이제일제당 (주) 신규한 디히드로리포일 아세틸기전이효소 변이체 및 이를 이용한 l-발린 생산 방법
KR102306010B1 (ko) * 2021-04-07 2021-09-27 씨제이제일제당 (주) 신규한 분지쇄아미노산 투과효소 변이체 및 이를 이용한 l-발린 생산 방법
CN116785418A (zh) * 2022-12-07 2023-09-22 深圳万可森生物科技有限公司 一种鱼源无乳链球菌亚单位疫苗及其制备方法与应用
CN120028542B (zh) * 2025-01-17 2025-11-25 宁夏医科大学 血清抗体IgG特异识别其疫苗株抗原谱及其筛选方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033600T2 (de) * 1989-03-09 2001-04-05 American Cyanamid Co., Madison Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
US5980908A (en) * 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
US5456907A (en) 1992-01-10 1995-10-10 Helene Curtis, Inc. Cysteamine permanent wave composition and method
JPH11514870A (ja) * 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
EP1036321A1 (de) * 1997-12-05 2000-09-20 Intercell Biomedizinische Forschungs- und Entwicklungs GmbH Verfahren und zellen zum "screening" von "combinatorial libraries"
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
WO1999057312A1 (en) * 1998-04-30 1999-11-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. New method for the selection of clones of an expression library involving rearraying
WO1999067376A1 (en) * 1998-06-25 1999-12-29 Institut Pasteur Exhaustive analysis of viral protein interactions by two-hybrid screens and selection of correctly folded viral interacting polypeptides
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
AT407643B (de) * 1999-02-01 2001-05-25 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
CA2721199A1 (en) * 1999-05-05 2000-11-16 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
EP1238102B1 (de) * 1999-08-06 2008-11-12 Oragenics, Inc. Mikrobielle polynukleotide, die während der infekton eines wirts exprimiert werden
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
JP4852211B2 (ja) 2000-03-21 2012-01-11 メルク アンド カンパニー インコーポレイテッド 原核生物における必須遺伝子の同定
RU2293573C2 (ru) 2000-06-08 2007-02-20 Интерселл Аг Иммуностимулирующие олигодезоксинуклеотиды
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
US20040170642A1 (en) 2000-08-17 2004-09-02 Jorg Fritiz Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2320233A1 (de) 2001-06-15 2011-05-11 Inhibitex, Inc. Kreuzreaktive monoklonale und polyklonale Antikörper, die Oberflächenprotein aus Koagulasenegativen Staphylococci und Staphylococcus aureus erkennen
WO2003011899A2 (en) 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
SI1651166T1 (sl) 2003-07-24 2010-06-30 Merck Sharp & Dohme Polipeptidi za induciranje zaščitnega imunskegaodgovora proti stafilokoknem eureusu
EP1734615B1 (de) 2005-06-13 2008-10-08 Research In Motion Limited Elektrischer Verbinder und elektrisches System für ein Bauteil in einem elektronischen Gerät

Also Published As

Publication number Publication date
DE60207194T2 (de) 2006-08-03
RU2289817C2 (ru) 2006-12-20
AU2010200549A1 (en) 2010-03-04
EP1630172B1 (de) 2015-06-10
US7771728B2 (en) 2010-08-10
EP2319861A1 (de) 2011-05-11
CN101492496A (zh) 2009-07-29
US20080038287A1 (en) 2008-02-14
AU2002247641B8 (en) 2008-03-13
IL211037A (en) 2013-07-31
SK10492003A3 (sk) 2004-07-07
US20110020402A1 (en) 2011-01-27
KR20080029016A (ko) 2008-04-02
NZ551802A (en) 2008-04-30
AT410798B (de) 2003-07-25
JP2008291035A (ja) 2008-12-04
US7968297B2 (en) 2011-06-28
ZA200305764B (en) 2004-07-26
IL186706A0 (en) 2008-02-09
CZ20032201A3 (en) 2004-03-17
PL367125A1 (en) 2005-02-21
EP1616876A3 (de) 2006-04-12
PL214482B1 (pl) 2013-08-30
KR100851728B1 (ko) 2008-08-11
CA2436057C (en) 2012-12-18
HUP0402048A2 (hu) 2005-01-28
CA2436057A1 (en) 2002-08-01
ES2252438T3 (es) 2006-05-16
IL211037A0 (en) 2011-04-28
HUP0402048A3 (en) 2010-01-28
BR0207067A (pt) 2004-06-15
RU2003125967A (ru) 2005-03-10
JP2004531476A (ja) 2004-10-14
NO20033364L (no) 2003-09-24
CA2792244A1 (en) 2002-08-01
WO2002059148A2 (en) 2002-08-01
EP1355930A2 (de) 2003-10-29
EP1630172A3 (de) 2006-05-03
US8715688B2 (en) 2014-05-06
KR20030082574A (ko) 2003-10-22
EP1355930B1 (de) 2005-11-09
CN1649894A (zh) 2005-08-03
PL209115B1 (pl) 2011-07-29
IL186706A (en) 2010-12-30
US20130034575A1 (en) 2013-02-07
AU2007234519A1 (en) 2007-12-13
IS6895A (is) 2003-07-25
KR20080107477A (ko) 2008-12-10
WO2002059148A3 (en) 2003-07-31
EP1616876A2 (de) 2006-01-18
NZ565349A (en) 2009-07-31
AU2002247641B2 (en) 2007-08-23
JP5053933B2 (ja) 2012-10-24
NO20033364D0 (no) 2003-07-25
IL211038A0 (en) 2011-04-28
AU2007234519B2 (en) 2009-11-12
KR20090101973A (ko) 2009-09-29
NZ540764A (en) 2008-03-28
ATE309268T1 (de) 2005-11-15
WO2002059148A9 (en) 2002-10-31
NZ527440A (en) 2006-02-24
DE60207194D1 (de) 2005-12-15
PL392964A1 (pl) 2011-01-03
US8323660B2 (en) 2012-12-04
WO2002059148A8 (en) 2003-01-16
EP2412722A1 (de) 2012-02-01
DK1355930T3 (da) 2006-03-06
MXPA03006702A (es) 2005-04-08
KR100901915B1 (ko) 2009-06-10
IL157082A0 (en) 2004-02-08
EP1630172A2 (de) 2006-03-01
US20050037444A1 (en) 2005-02-17
EP2322539A2 (de) 2011-05-18
EP2322539A3 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
ATA1302001A (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
DE60126156D1 (de) Verfahren und vorrichtung zur herstellung von knochenzement
DE60206472D1 (de) Verfahren und vorrichtung zur herstellung von mineralwolle
DE50006246D1 (de) Verfahren und vorrichtung zur herstellung von borstenwaren und danach hergestellte borstenwaren
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
DE60301350D1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
DE60328150D1 (de) System und Methode zur Erzeugung von Anfangs-Vektoren
DE60232605D1 (de) Verfahren zur herstellung von durchblasgetrocknetem tissueprodukt mit abdampfrückgewinnung
AT4947U3 (de) Vollnarbiges rindnappaleder und verfahren zur herstellung desselben
DE60334747D1 (de) Verfahren und Vorrichtung zur Herstellung von Microarrays
EP1576108A4 (de) Nitrilasen, diese codierende nukleinsäuren sowie verfahren zur herstellung und verwendung davon
DE50304943D1 (de) Verfahren und vorrichtung zur herstellung von borsten
DE60232600D1 (de) Verfahren und vorrichtung zur herstellung von percarbonsäure
EP1487480A4 (de) Fusionsmoleküle und verfahren zur behandlung von immunkrankheiten
ATE246512T1 (de) Verfahren zur herstellung von inaktivierten, w/ö emulsion adjuvierten, impfstoffen
DE50306404D1 (de) Verfahren und vorrichtung zur herstellung von vorgarnlunte
ATE531724T1 (de) Verfahren zur herstellung von peptiden
ATE509892T1 (de) Verfahren zur herstellung von magnetitteilchen
DE60316020D1 (de) Verfahren und vorrichtung zur herstellung und rückführung von fluor
ATE538209T1 (de) L-threonin herstellendes bakterium und verfahren zur herstellung von l-threonin
DE50208126D1 (de) Verfahren zur Herstellung von Aminoalkylsilanen und Alkylaminen
ATA12999A (de) Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen
ATE406806T1 (de) Verfahren zur herstellung von sojazuckern und davon abgeleitetes produkt
DE60229365D1 (de) Verfahren zur Aktivierung von Antigenen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee